TPF Followed by Cetuximab and IMRT Plus Carbon Ion Boost for Locally Advanced Head and Neck Tumors

Inclusion Criteria:

* Signed written informed consent,
* Age of 18 to 70 years,
* Life expectancy of at least 6 month,
* Ability of subject to understand character and individual consequences of clinical trial,
* Histologically confirmed locally advanced (stage III or IV), non-metastatic squamous cell carcinoma of oro-, hypopharynx and larynx (T2-4, any N, M0),
* Oral cavity or oro- , hypopharynx or laynx as the primary tumor site,
* At least one uni-measurable lesion according to the RECIST criteria, Karnofsky Performances Status \> 70%,
* Adequate bone marrow function: neutrophils \> 1.5 x 109/L, platelets \> 100 x 109/L, hemoglobin \> 10.0 g/dL,
* Adequate liver function: Bilirubin \< 1.5 mg/dL, SGOT, SGPT \< 3 x ULN, GGT \< 5 x ULN,
* Adequate renal function: GFR\> 70 ml/min,
* Negative serum/urine Beta-HCG test in women of childbearing potential,
* Women of childbearing potential: willingness to use effective contraceptive method, defined as the concomitant use of either an intrauterine pessary (IUP) or contraceptive pill and in both cases, condoms for the treatment duration and 2 months thereafter. Women of non-childbearing potiential are those who are post-menopausal for at least 1 year or sterilized,
* Men of procreative potential: willingness for effective prevention of procreation, defined as a use of condoms and a use of either an intrauterine pessary (IUP) or a contraceptive pill by his partner for the treatment duration and 2 months thereafter,
* Subject's consent to collect blood and/or tumor tissue samples for proteomics and genomics. If a patient does not consent, no samples for proteomics and genomics will be taken. Nonetheles, he/she may be enroled in the study

Exclusion Criteria:

* Previous systemic chemotherapy, radiotherapy or surgery for carcinoma of the head, neck and larynx,
* Nasopharyngeal Carcinoma,
* Prior exposure to EGFR pathway targeting therapy,
* Evidence of distant metastases.
* Other serious illness or medical conditions:
* Unstable cardiac disease despite treatment, congestive heart failure NYHA grade 3 and 4,
* Significant neurologic or psychiatric disorders including dementia or seizures,
* Active disseminated intravascular coagulation,
* Other serious underlying medical conditions which in the opinion of investigator could impair the ability of the patient to participate in the study,
* Symptomatic peripheral neuropathy Common Toxicity Criteria (CTC) grade 2 or higher,
* ototoxicity CTC grade 2 or higher, except if due to trauma or mechanical impairment due to tumor mass,
* Participation in other interventional trial within the last 30 days§§,
* Surgery within the last 30 days,
* Known allergic/hypersensitivity reaction to any drugs scheduled for the study treatment,
* Women: pregnant or breast-feeding,
* Known drug abuse,
* Other previous malignancy within 5 years, with exception of a history of a previous, adequately treated, basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix,
* Legal incapacity or limited legal capacity,
* Medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent.